Sanofi Gets A Helping Hand From US FDA At Dengvaxia Review
Executive Summary
After split verdicts on efficacy and safety for Sanofi’s proposed population for the dengue vaccine, FDA added two new questions limited to pediatric use, which drew strong advisory committee support.